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Summary
In this review, we present the fi ndings from the literature on several new molecules that can be targeted in the mela-
noma treatment process, especially metastatic melanoma, since fi ve-year survival rates are below 20%. Recently, melanoma 
has been defi ned by mutations that occur in oncogenes and lead to melanomagenesis. A mutation in BRAF gene selects the 
patients for targeting therapy with BRAF inhibitors. Although BRAF inhibitor therapy is associated with clinical benefi t, the 
majority of patients with the BRAFV600-mutated metastatic melanoma develop resistance, usually within the fi rst year. 
Clinically signifi cant discrepancy in BRAF status, between primary melanoma and its metastasis were detected in about 
15% of cases. There are no specifi c recommendations on BRAF re-testing, but might be clinically relevant to repeat testing 
on recent metastatic sites in cases of previous BRAF wild type results. 
KEY WORDS: metastatic melanoma, BRAF, p53, signaling pathway, mutations
MUTACIJE KOD MELANOMA U PROGRESIJI
Sažetak
U ovom preglednom radu, predstavljena su saznanja iz literature o nekoliko novih molekula na koje može biti usmje-
ren razvoj ciljane terapije u procesu liječenja melanoma, osobito metastatskog, gdje je petogodišnje preživljenje manje od 
20%. Melanomi su sve češće defi nirani mutacijama u onkogenima koje dovode do maligne trasnformacije. Mutacije BRAF 
gena određuju bolesnike za ciljanu terapiju BRAF inhibitorima. Iako bolesnici imaju kliničku korist od terapije, većina bole-
snika s BRAFV600 mutiranim metastatskim melanomom postanu rezistentni unutar godinu dana. Klinički značajne razlike 
u BRAF statusu između primarnog melanoma i metastaza, javljaju se u oko 15% slučajeva. Nema specifi čnih preporuka za 
ponovno BRAF testiranje, ali može biti klinički značajno ponoviti testiranje na novonastalim metastazama, u slučajevima 
prethodnih BRAF rezultata divljeg tipa.
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INTRODUCTION
Melanoma is a malignant tumor of melano-
cytes (MM). Melanoma development correlates 
with the DNA damage caused by ultraviolet light 
(UV). In recent years the melanoma rate is in-
creasing, probably due to increased unprotected 
exposure to UV radiation from either the sun or a 
variety of tanning devices. Apart sun exposure, 
older age, Caucasian raise or pre-existing moles, 




Melanoma early stage, histologically is re-
ferred as the radial growth phase of melanocytes, 
spreading in the papillary dermis in depth less 
than 1 mm (Clark 2, Breslow 1). Deeper invasion 
of melanoma in the papillary dermis, referring as 
vertical growth phase, enables melanoma reach-
ing the blood vessels and spreading to other parts 
of the body. Early stage melanoma often is cured 
surgically; otherwise, the treatment of choice is 
traditional cytotoxic chemotherapy, targeted ther-
apies, and immune-based therapies (2). Metastatic 
melanoma (MM) treatment, with 5-year survival 
rate less than 20% due to resistance to standard 
chemotherapy, still remains a challenge (2). Al-
though, MM is classifi ed according to histology 
(Clark, Breslow, TNM), recently is defi ned by mu-
tations that occur in oncogenes and lead to mela-
nomagenesis. 
Physiological condition
The melanocytes physiological role is pro-
ducing the pigment melanin that protects the 
body from the sunlight damaging eff ect. UV light 
damages the DNA directly and indirectly. Direct 
damage occurs when DNA absorbs UV photons, 
resulting in thymine-thymine dimers while indi-
rect damage occurs via production of reactive ox-
ygen radicals that can cause single-strand DNA 
breaks, or oxidize the nucleobases (3,4). If unre-
pared, aforementioned damages can cause inaccu-
rate synthesis during DNA replication or repair, 
leading to mutations (4). 
Sunlight damages kerationcytes positioned 
in the upper layers of skin, activating the DNA 
damage repair mechanism via p53 protein and 
also induce signalling towards the melanocytes to 
produce the melanin (3). Short-term sunlight ex-
posure results in changed distribution of melanin 
granules (melanosomes) from the melanocytes to 
keratinocytes. Long-term tanning increase pig-
mentation by melanocytes modulation through 
keratinocytes signaling (1,3). Keratinocytes ex-
crete alpha-melanocyte stimulating hormone 
(aMSH) which binds to the melanocortin-1 recep-
tor (MC1R) on the surface of the melanocyte, acti-
vates microphthalmia associated transcription 
factor (MITF) and induces the production of mela-
nin (4,5). On chronically sun-damaged skin, ke-
ratinocytes modulates melanocytes over c-KIT re-
ceptor signaling and activation of the RAS-RAF-
MEK-ERK pathway (MAPK), which is crucial in 
melanocyte development and proliferation. RAS 
proteins can activate the MAPK pathway (in-
volved in cell diff erentiation and proliferation) or 
the PI3K/AKT/mTOR pathway (involved in cell 
survival) (4,5). Somatic mutations in these path-
ways are the main driver of malignancy. 
Mutation events
A mutation of tumor suppressor gene TP53 is 
one of the earliest events in melanocytes caused 
by UV radiation, resulting in non-functional p53 
protein, detected in over 40% of melanomas (6,7). 
Viros and colleagues showed that induction of 
TP53 mutation, or its inactivation, accelerate 
BRAF-driven melanogenesis (6). Functional p53 
protein is a major regulator of cell cycle arrest dur-
ing sun-damaged DNA repair or p53 induced ap-
optosis (6,7). Conventional chemotherapy usually 
targets p53 function, but melanomas are resistant 
to p53 dependent apoptosis, which might be a rea-
son for melanoma resistance to chemotherapy (8). 
According to Terzian et al. increased p53 can pre-
vent progression of nevi to melanoma and specifi c 
activation of p53 might be an eff ective strategy to 
reduce the risk of melanoma (7). 
BRAF mutation is one of the early events in 
malignant transformation of melanocytes. Still, it 
is considered that single mutation is not suffi  cient 
Figure 1. Schematic diagram of important signaling pathways in 
melanoma. Signaling through MC1R receptor activates melanin 
synthesis, c-KIT signaling is essential for melanocyte develop-




to induce melanoma, since BRAFV600 mutations 
are frequently found in benign and dysplastic 
melanocytic nevi (9). Thus, the NCCN Clinical 
Practice Guidelines in Oncology (2017) do not rec-
ommend the BRAF mutation testing of primary 
cutaneous melanoma, unless required for system-
ic therapy (2). UV-induced mutations, as loss of 
function in tumor suppressor gene phosphatase 
and tensin homolog, PTEN (found in 40-60% of 
melanomas), mutations in cyclin-dependent ki-
nase inhibitor 2A (CDKN2A) (found in ~40% of 
melanomas) and over-expression of MDM4 pro-
tein (found in ~60% of melanomas), both acting as 
a negative regulator of p53 protein, were also de-
scribed (1,3,4). 
BRAF mutations
The BRAF gene encodes a protein which 
plays a role in the control of cell proliferation, dif-
ferentiation, infl ammatory responses and apopto-
sis via the mitogen activated protein kinase 
(MAPK) pathway (10). Mutations of BRAF gene 
have been found in ~60% of all MM and the most 
prevalent mutations are located on codon 600 of 
the BRAF gene. The most common BRAFV600E 
mutation is the result of a transversion of thymine 
to adenine at nucleotide 1799 (T1799A), and sub-
sequently a substitution of valine (V) for glutamic 
acid (E) in position 600 of BRAF protein. Less com-
mon substitutions are of V for lysine (V600K (~8–
20%)), arginine (V600R (1%)), leucine (V600M 
(0.3%)), and aspartic acid (V600D (0.1%)). Some 
nonV600 mutations (K601E, D594N) are also 
found in a low percentage of patients, but till to-
day without known clinical signifi cance. RAF mu-
tation results in constitutive activation of the 
MAPK signaling pathway (10,11). 
Patients with the detected BRAFV600 muta-
tion are candidates for  the BRAF inhibitor thera-
py with vemurafenib and dabrafenib, that become 
an important step forward in the treatment of mel-
anomas (9,12). Although BRAF inhibitor therapy 
is associated with clinical benefi t, the majority of 
patients with the BRAFV600 mutated MM devel-
op resistance to vemurafenib, usually within the 
fi rst year. Mechanisms of resistance to the BRAF 
inhibitors might be acquired by amplifi cation or 
mutations in other genes evolved in the same 
pathways. Amplifi cation of BRAF, CRAF, insulin-
like growth factor 1 receptor (IGF1R), hepatocyte 
growth factor (HGF), and platelet-derived growth 
factor receptor (PDGFRβ), and mutations in 
NRAS, MEK1, NF1 and PI3KCA genes were de-
tected. As Shi and colleagues reported, 70% of the 
resistance is acquired through the MAPK reactiva-
tion. NRAS mutations were detected in 18%, 
KRAS in 7% and BRAF amplifi cation or alterna-
tive splicing were detected in more than 40% of 
melanoma resistant to BRAF inhibitors (12). 
The majority of tumors are heterogeneous, 
which has recently been confi rmed in melanomas. 
The molecular profi le of MM can change over 
time, and the amount of mutations increase with 
progression (13). Furthermore, some mutually ex-
clusive mutations (eg. BRAF and NRAS) can be 
present in the same tumor due to its clonal hetero-
geneity (13,14). Recently, discrepancy in BRAF 
mutation between primary melanoma and metas-
tases and between diff erent metastatic sites of re-
current melanoma has been documented. Yanco-
vitz  et al. detected discordant BRAF status among 
two metastases of the same patients in 26% and 
between primary melanoma and a metastasis in 
33% (15). Heinzerling analyzed up to 13 tumour 
samples per patient and found discordant results 
in 18.9% of patients while discordance between 
primary tumours and metastases was detected in 
44% of patients (16). Yet, Hannah et al. found dis-
cordance between primary melanoma and brain 
metastasis in only 14% of cases (17). Meta-analysis 
performed by Valachis and Ullenhag detected dis-
crepancy in BRAF status between primary and 
metastatic lesions in 13.4% and between two met-
astatic lesions in 7.3% of cases (18). Meta-analysis 
by Grzywa and colleagues found overall hetero-
geneity in 8.1% of melanomas and 16% heteroge-
neity in BRAF-mutated melanomas. They also re-
corded discrepancy in BRAF status between pri-
mary and metastatic lesions in 15.5% of cases (19). 
Melanomas heterogeneity still remains controver-
sial and Riveiro-Falkenbach suggested that incon-
sistency between primary and metastatic melano-
mas can be a result of diff erent molecular tests or 
quality of samples used for BRAF detection (20). 
Other driver mutations
MEK1 (MAP2K1) is a central mediator in the 
MAPK signaling pathway. Somatic mutations in 
MEK1 have been found in 6–7% of MM and often 
occur together with BRAF or NRAS mutations. 
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The MEK inhibitor therapy (trametinib and cobi-
metinib) is used for the treatment of BRAFV600E-
mutated melanoma resistant to BRAF inhibitors. 
Mutations in NRAS have been found in ~13–25% 
of all MM with the result of constitutive activation 
of the MAPK pathway. Our pilot study detected 
NRAS mutations in over 60 % of BRAF wild type 
metastatic melanomas (not published), namely a 
substitution of glutamine to arginine/lysine/leu-
cine at position 61 (Q61R/K/L). NRAS mutations 
might respond to MEK inhibitor-based therapy 
(1,3,10,11).
Mutations in G proteins (GNA11 and GNAQ) 
have been found in up to 2.3% of all MM. Expres-
sion of G proteins results in melanocyte transfor-
mation and increased signaling through the 
MAPK pathway (1,3,10,11). 
Neurofi bromin 1 (NF1) is a tumor suppressor 
gene that suppresses the function of the RAS pro-
tein. NF1 mutations occur in 11.9% of MM. Inacti-
vation or loss of NF1 function might play a role in 
melanomagenesis. NF1 mutations might be respon-
sible for resistance to RAF/MEK targeted therapies. 
Currently, there is no therapy directed to G-pro-
teins or NF1 (1,3,10,11). 
C-KIT (CD117) is a receptor tyrosine kinase 
that activates the PI3K pathway, the MAPK path-
way, and other pathways involved in mediating 
pro-growth and pro-survival signaling. Mutations 
or amplifi cation of KIT gene has been founded in 
3-9% of all MM. Phase II clinical trials have dem-
onstrated clinical responses of c-KIT-mutated 
melanoma to imatinib, sunitinib, sorafenib, and 
nilotinib, and everolimus after acquiring resist-
ance to imatinib (1,3,10,11). 
The CTNNB1 gene encodes the ß-catenin 
that regulates cell growth and adhesion of epithe-
lial cells regulated via glycogen synthase kinase 3 
beta (GSK3β). Somatic mutations in CTNNB1 
have been found in 2–7% of MM. Concurrent mu-
tations in ß-catenin and NRAS act synergistic in 
promoting melanoma formation (1,3,10,11).
Several other amplifi cations (MITF, MYC, 
AKT3), and mutations in genes (AT-rich interac-
tive domain-containing protein 2 (ARID2), protein 
phosphatase 6 (PPP6C), sorting nexin 31 (SNX31), 
rac family small GTPase 1 (RAC1); serine/threo-
nine kinase 19 (STK19), and transforming acidic 
coiled-coil-containing protein 1 (TACC1)) were 
discovered recently, that might be a potential tar-
get in melanoma therapy (1,3,10,11).
CONCLUSION
Clinically signifi cant discrepancy in BRAF 
status, between primary melanoma and its metas-
tasis, is reported in about 15% of cases. There are 
no specifi c recommendations about BRAF retest-
ing, although repeating testing on recent metastat-
ic sites might be clinically relevant, especially in 
cases of previous BRAF wild type results. Despite 
the fact that changes in melanoma cells occur dur-
ing progression, there is no additional testing rec-
ommendations till today. Recent literature, dis-
covered many potential targets for developing a 
specifi c therapy, of which we presented the most 
promising one.
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